Cyclodextrin-Nle3-A(1-7) compositions and their use

Patent metadata

Field	Value
Publication number	US-10987403-B2
Application number	US-201816491042-A
Country	US
Kind code	B2
Filing date	Mar 9, 2018
Priority date	Mar 10, 2017
Publication date	Apr 27, 2021
Grant date	Apr 27, 2021

Abstract

Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.

First claim

We claim:

1. A method for treating a subject, comprising orally administering to a subject a composition comprising cyclodextrin and a peptide comprising or consisting of Nle3-A(1-7) [Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1)], or a pharmaceutically acceptable salt thereof, in an amount effective to treat a disorder that may benefit from treatment with a peptide comprising or consisting of Nle3-A(1-7) or a pharmaceutically acceptable salt thereof, wherein:
(a) the subject will be undergoing, is undergoing or has undergone chemotherapy, radiation therapy, and/or bone marrow transplantation;
(b) the subject has chemotherapy induced myelosuppression and/or myelodysplastic syndrome (MDS); or
(c) the subject has a disorder selected from the group consisting of multiple sclerosis (MS) and muscular dystrophy (MD).

2. The method of claim 1 , wherein the subject will be undergoing, is undergoing or has undergone chemotherapy, radiation therapy, and/or bone marrow transplantation.

3. The method of claim 1 wherein the subject has chemotherapy induced myelosuppression and/or myelodysplastic syndrome (MDS).

4. The method of claim 1 , wherein the subject has a disorder selected from the group consisting of multiple sclerosis (MS) and muscular dystrophy (MD).

5. The method of claim 1 , wherein the subject is a human subject.

6. The method of claim 5 , wherein the subject is less than 18 years of age.

7. The method of claim 1 , wherein the composition comprises an Nle3-A(1-7) inclusion complex.

8. The method of claim 1 , wherein the cyclodextrin comprises β-cyclodextrin.

9. The method of claim 1 , wherein the cyclodextrin and peptide are present in a molar ratio of between about 1:1 and 10:1.

10. The method of claim 1 , wherein the cyclodextrin and peptide are present in a molar ratio of between about 1:1 and 5:1.

11. The method of claim 1 , wherein the cyclodextrin and peptide are present in a molar ratio of between about 1:1 and about 2:1.

12. The method of claim 1 , wherein the peptide is present at a concentration of between about 0.05 μg/mg (w/w) and about 500 μg/mg (w/w).

Assignees

• Gaffney Kevin J
• Louie Stan G
• Rodgers Kathleen E
• Univ Southern California

Inventors

• Gaffney Kevin J
• Louie Stan G
• Rodgers Kathleen E

Classifications

• A61K47/6951

  using cyclodextrin (cyclodextrins used as simple excipients A61K47/40) · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61K38/085 Primary

  Angiotensins · CPC title

• A61K47/40

  Cyclodextrins; Derivatives thereof · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title